Genetic breakthrough in childhood kidney cancer
Scientists from the Princess Máxima Center, together with international partners, discovered that a form of kidney cancer in children, Wilms tumor, contains many more genetic changes than previously thought. This discovery could lead to new, more targeted treatment options in the future, including immunotherapy.
Scientists from the Princess Máxima Center, working with partners from the Wellcome Sanger Institute, the University of Cambridge and Great Ormond Street Hospital in the UK, have used new DNA technologies to examine tumors from young children with a kidney tumor in detail. They used advanced sequencing, a method that allows scientists to quickly and extensively read out the entire genetic material of the tumor.
More variation than expected
By genetically mapping individual cells of Wilms tumors, the researchers found many more mutations per cell than expected. Dr. Jarno Drost, research group leader at the Princess Máxima Center and Oncode Institute, is co-senior author of the new study. He says: ‘Our findings show that the genetic variation of some childhood tumors is much higher than previously thought. In some cases, it’s even comparable to that of tumors in adults.’ The findings change the assumptions we had of childhood cancer and also point to opportunities for new or existing therapies.
Implications for treatment
Tumors with a lot of genetic variation can adapt more quickly, so a treatment can stop working. But large variation in the tumor also offers targets for precision therapies such as immunotherapy. These treatments, now mainly used in adult oncology, could in future also be used in children with Wilms tumor.
Unique genetic change in congenital tumors
Another important discovery in the research is a specific genetic change (in the FOXR2 gene) that already occurs during embryonic development. This mutation appears to be responsible for a rare congenital form of Wilms tumor, with specific features under the microscope, and with a characteristic genetic profile. Spotting this mutation could in future help to personalize treatment for children with a Wilms tumor.
Careful balance
Jarno Drost: ‘The treatment of Wilms tumors requires a careful balance: targeting the tumor and preventing the cancer from coming back, with as little impact as possible on the quality of life of a child and their family. We now better understand which genetic changes cause these tumors, and can better pick out these genetic subgroups. Our research marks an important step towards more targeted and child-friendly treatments.’
This study was published today in Nature Communications. The research was led by Dr. Sam Behjati of the Wellcome Sanger Institute in the UK and Dr. Jarno Drost of the Princess Máxima Center and Oncode Institute. The research was funded by the Alpe d’HuZes/KWF fund, ERC, the Wellcome Trust and the Little Princess Trust.
Rhabdoid tumor cells targeted through their building blocks
PhD candidate Marjolein Kes has identified new therapeutic targets for the treatment of rhabdoid tumors (MRT). In the laboratory, Kes found that inhibiting the production of DNA building blocks slows the division of tumor cells and can even cause them to disappear. These findings form the basis for the development of a new clinical study. Yesterday, she received her PhD from Utrecht University.
Health Starts in the Community, Not in the Hospital
A person’s health is shaped by more than access to medical care. Factors such as income, housing, stress, social environment, and access to essential services all play an important role. That is why researchers, healthcare professionals, students, and residents are working together to reduce health inequalities and create healthier communities.
Heineken Young Scientists Award for Miguel Leung
Miguel Leung, group leader at the Hubrecht Institute since 2024, has been awarded the Heineken Young Scientists Award 2026. This award recognizes young researchers who have made outstanding scientific achievements, setting an example for other young scientists. With his research group at the Hubrecht Institute, Miguel Leung investigates the 3D structure of protein complexes, tiny machines at work inside each of our cells. The group focuses on highly specialized cells that perform specific functions, such as sperm and egg cells.
Opening Utrecht Science Week with keynote by Juliette Legler on the hidden influence of environmental chemicals
On Friday, September 25, the annual science festival ‘Utrecht Science Week’ kicks off once again at Utrecht Science Park. We are pleased to announce that this year, Prof. Dr. Ir. Juliette Legler will deliver the Utrecht Science Lecture. Juliette Legler is Professor of Toxicology at the Faculty of Veterinary Medicine at Utrecht University and leads the ‘One Health Toxicology’ group at the Institute for Risk Assessment Sciences (IRAS).